Disrupting this axis with SETD8 inhibitor reduces SCC cells growth significantly and highlights that SOX2–BCL11A–SETD8 regulatory pathway may be a potential candidate framework for drug development in NSCLC. This evidence concerns the gene BCL11A and non-small cell lung carcinoma.